The FDA has denied full approval for Lumakras (sotorasib) to treat adults with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
FDA Denies Regular Approval of Lumakras for KRAS G12C-Mutated NSCLC
1 year ago
56
Related
Popular
Reduce your risk of cancer: get involved and have fun
1 year ago
227
English (US) · Copyright © 2019 - 2025 | Whatiscancer.net | All Rights Reserved.